Search

Search Constraints

You searched for: Author/Creator Nooka, Ajay K

Search Results

1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Issue 2 (February 2020)

4. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)

6. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)

7. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)

8. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)

9. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)

10. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Issue 2 (12th July 2020)